PLUS THERAPEUTICS INC

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2024	2023	2024	2023
Grant revenue	$1,279	$1,854	$2,956	$2,360
Operating expenses:
Research and development	2,773	1,420	5,536	4,403
General and administrative	2,203	1,924	4,416	4,169
Total operating expenses	4,976	3,344	9,952	8,572
Loss from operations	(3,697)	(1,490)	(6,996)	(6,212)
Other income (expense):
Financing expense	(3,545)	—	(3,545)	—
Change in fair value of warrants	4,694	—	4,694	—
Warrant issuance costs	(432)	—	(432)	—
Interest income	67	120	139	171
Interest expense	(27)	(112)	(61)	(246)
Total other income (expense)	757	8	795	(75)
Net loss	$(2,940)	$(1,482)	$(6,201)	$(6,287)
Per share information:
Net loss per share of common stock - basic	$(0.45)	$(0.59)	$(1.15)	$(2.60)
Weighted average number of shares of common stock outstanding - basic	6,500,831	2,509,378	5,411,382	2,415,221
Net loss per share of common stock - diluted	$(0.71)	$(0.59)	$(1.45)	$(2.60)
Weighted average number of shares of common stock outstanding - diluted	10,742,924	2,509,378	7,532,428	2,415,221

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.